Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer Schering...

Micromet Enters Into Agreement for Solid Tumor BiTE Antibody with Bayer
Schering Pharma AG

BETHESDA, Md., Jan. 12 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq:
MITI), a biopharmaceutical company developing novel, proprietary antibodies
for the treatment of cancer, inflammation and autoimmune diseases today
announced the signing of an option, collaboration and license agreement with
Bayer Schering Pharma AG, Germany, under which Bayer Schering Pharma has the
exclusive option to obtain a license to one of Micromet's preclinical BiTE
antibodies against an undisclosed oncology target.

Under the terms of the agreement, Bayer Schering Pharma will pay Micromet a
Euro 4.5 million fee (approx. US$ 6 million) to secure a one year option on a
specific BiTE antibody. Bayer Schering Pharma may exercise this option prior
to January 5, 2010 through the additional payment of an option exercise fee.
The exercise of the option would trigger a formal collaboration between
Micromet and Bayer Schering Pharma on the development of the BiTE antibody
through the completion of phase 1 clinical trials, at which point Bayer
Schering Pharma would assume full control of the further development and
commercialization of the BiTE antibody. Micromet would be eligible for an
option exercise fee and milestone payments of up to Euro 290 million (approx.
US$ 390 million) in total and up to double digit royalties based on tiered net
sales of the product. In addition, Micromet would be reimbursed for its R&D
expenses incurred in connection with the development of the BiTE antibody in
the collaboration with Bayer Schering Pharma.

"We are very pleased with Bayer Schering Pharma's interest in this preclinical
BiTE antibody program and their financial commitment to secure exclusive
access for the next 12 months. This deal represents further validation of our
BiTE antibody technology by a major oncology company," said Christian Itin,
Micromet's Chief Executive Officer.

"Oncology is one of our core growth areas and biologicals are a key focus of
our strategy. We are excited about Micromet's BiTE antibody technology and
believe BiTE antibodies represent a novel and promising approach to cancer
therapy," said Prof. Andreas Busch, Member of the Board of Management of Bayer
Schering Pharma AG responsible for Global Drug Discovery.

About BiTE Antibodies

BiTE(R) antibodies are designed to direct the body's cytotoxic, or cell-
destroying, T cells against tumor cells, and represent a new therapeutic
approach to cancer therapy. Typically antibodies cannot engage T cells because
T cells lack the appropriate receptors for binding antibodies. Previous
attempts have shown the potential of T cells to treat cancer, but the
therapeutic approaches tested to date have been hampered by cancer cells'
ability to escape recognition by T cells. The use of BiTE antibodies that are
specifically designed to engage T cells for attacking cancer cells may provide
a more effective anti-tumor approach than conventional monoclonal antibodies.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with
offices in Bethesda, MD and Munich, Germany. The Company is focused on
developing novel, proprietary antibodies for the treatment of cancer,
inflammation and autoimmune diseases. The Company's novel antibody technology
is based on its proprietary BiTE antibody platform, representing a new class
of antibodies that specifically activate T cells from the patient's own immune
system to eliminate cancer cells or other disease related cells. Four of the
Company's antibodies are currently in clinical trials, with the remainder of
its product pipeline in preclinical development. The Company's lead program is
a BiTE(R) antibody known as blinatumomab, or MT103. It is in a phase 2
clinical trial for the treatment of patients with acute lymphoblastic leukemia
and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's
lymphoma. Micromet is developing blinatumomab in collaboration with
MedImmune, LLC, a subsidiary of AstraZeneca plc. Micromet's second BiTE
antibody in clinical development is MT110, which targets the epithelial cell
adhesion molecule (EpCAM). The Company owns all rights MT 110, which is
currently in a phase 1 clinical trial for the treatment of patients with solid
tumors. The Company's third clinical stage antibody is adecatumumab, also
known as MT201, a traditional human monoclonal antibody that targets
EpCAM-expressing solid tumors. Micromet is developing adecatumumab in
collaboration with Merck Serono in a phase 1b clinical trial evaluating
adecatumumab in combination with docetaxel for the treatment of patients with
metastatic breast cancer. Micromet licensed a fourth clinical stage antibody,
MT 293, to TRACON Pharmaceuticals, Inc. MT 293 is developed in a phase 1
clinical trial for the treatment of patients with cancer. The Company's
preclinical programs include MT 203 being developed in collaboration with
Nycomed. MT 203 is a traditional human antibody neutralizing the activity of
granulocyte/macrophage colony stimulating factor (GM-CSF), which has potential
applications in the treatment of inflammatory and autoimmune diseases, such as
rheumatoid arthritis, psoriasis, or multiple sclerosis. Additional BiTE
antibodies, targeting CEA, CD33, Her2, EGFR and MCSP, respectively, are in
different stages of preclinical development.

Forward-Looking Statements

This release contains certain forward-looking statements that involve risks
and uncertainties that could cause actual results to be materially different
from historical results or from any future results expressed or implied by
such forward-looking statements. These forward-looking statements include
statements regarding the efficacy, safety and intended utilization of our
product candidates, the development of our BiTE antibody technology, the
conduct, timing and results of future clinical trials, expectations of the
future expansion of our product pipeline and collaborations, and our plans
regarding future presentations of clinical data. You are urged to consider
statements that include the words "ongoing," "may," "will," "believes,"
"potential," "expects," "plans," "anticipates," "intends," or the negative of
those words or other similar words to be uncertain and forward-looking.
Factors that may cause actual results to differ materially from any future
results expressed or implied by any forward-looking statements include the
risk that product candidates that appeared promising in early research,
preclinical studies or clinical trials do not demonstrate safety and/or
efficacy in subsequent clinical trials, the risk that encouraging results from
early research, preclinical studies or clinical trials may not be confirmed
upon further analysis of the detailed results of such research, preclinical
study or clinical trial, the risk that additional information relating to the
safety, efficacy or tolerability of our product candidates may be discovered
upon further analysis of preclinical or clinical trial data, the risk that we
or our collaborators will not obtain approval to market our product
candidates, the risks associated with reliance on outside financing to meet
capital requirements, and the risks associated with reliance on collaborators,
including MedImmune, Merck Serono, TRACON and Nycomed, for the funding or
conduct of further development and commercialization activities relating to
our product candidates. These factors and others are more fully discussed in
Micromet's Annual Report on Form 10-K for the fiscal year ended December 31,
2007, filed with the SEC on March 14, 2008, as well as other filings by the
company with the SEC.

Any forward-looking statements are made pursuant to Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended, and, as such, speak only as of the date made.
Micromet, Inc. undertakes no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or
otherwise.

SOURCE Micromet, Inc.

US Media: Andrea tenBroek or Chris Stamm, both for Micromet, Inc.,
+1-781-684-0770, micromet@schwartz-pr.com; or European Media: Ludger Wess,
+49(40)8816-5964, ludger@akampion.com; or US Investors: Susan Noonan,
+1-212-966-3650, susan@sanoonan.com; or European Investors: Ines-Regina Buth,
+49(30)2363-2768, ines@akampion.com